{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhao Y"],"funding":["NCATS NIH HHS","NIAID NIH HHS","Crohn's & Colitis Foundation","National Institutes of Health","National Science Foundation"],"pagination":["103415"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6699176"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["205"],"pubmed_abstract":["Small molecule inhibitors of the epigenetic regulator bromodomain-containing protein 4 (BRD4) are potential therapeutics for viral and allergen-induced airway remodeling. A limitation of their preclinical advancement is the lack of detailed understanding of mechanisms of action and biomarkers of effect. We report a systems-level pharmacoproteomics in a standardized murine model of toll-like receptor TLR3-NFκB/RelA innate inflammation in the absence or presence of a highly selective BRD4 inhibitor (ZL0454) or nonselective bromodomain and extraterminal domain inhibitor (JQ1). Proteomics of bronchoalveolar lavage fluid (BALF) secretome and exosomal proteins from this murine model revealed increased, selective, capillary leak associated with pericyte-myofibroblast transition, a phenomenon bloc"],"journal":["Journal of proteomics"],"pubmed_title":["Pharmacoproteomics reveal novel protective activity of bromodomain containing 4 inhibitors on vascular homeostasis in TLR3-mediated airway remodeling."],"pmcid":["PMC6699176"],"funding_grant_id":["UL1 TR002373","576144","R21 AI133454","UL1 TR001439","P01 AI062885"],"pubmed_authors":["Zhang J","Tian B","Brasier AR","Zhao Y","Maroto R","Liu Z","Zhang Y","Ivannikov M","Kaphalia L","Sun H","Motamedi M","Zhou J","Calhoun WJ"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacoproteomics reveal novel protective activity of bromodomain containing 4 inhibitors on vascular homeostasis in TLR3-mediated airway remodeling.","description":"Small molecule inhibitors of the epigenetic regulator bromodomain-containing protein 4 (BRD4) are potential therapeutics for viral and allergen-induced airway remodeling. A limitation of their preclinical advancement is the lack of detailed understanding of mechanisms of action and biomarkers of effect. We report a systems-level pharmacoproteomics in a standardized murine model of toll-like receptor TLR3-NFκB/RelA innate inflammation in the absence or presence of a highly selective BRD4 inhibitor (ZL0454) or nonselective bromodomain and extraterminal domain inhibitor (JQ1). Proteomics of bronchoalveolar lavage fluid (BALF) secretome and exosomal proteins from this murine model revealed increased, selective, capillary leak associated with pericyte-myofibroblast transition, a phenomenon bloc","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Aug","modification":"2026-04-30T05:19:28.426Z","creation":"2020-08-19T07:10:03Z"},"accession":"S-EPMC6699176","cross_references":{"pubmed":["31195152"],"doi":["10.1016/j.jprot.2019.103415"]}}